The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
暂无分享,去创建一个
N. Brünner | J. Foekens | J. Klijn | M. Look | M. M. Gelder | F. Jänicke | M. Schmitt | H. Peters | H. Portengen | M. Kramer | M. M. Meijer-van Gelder | S. Henzen‐Logmans | W. van Putten | W. Putten | Harry A. Peters | M. Schmitt
[1] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[2] J. Kalbfleisch. Statistical Inference Under Order Restrictions , 1975 .
[3] Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. , 1980, European Journal of Cancer.
[4] A. Corti,et al. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[5] D. Belin,et al. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase , 1985, The Journal of cell biology.
[6] M. Cubellis,et al. The receptor for urokinase‐plasminogen activator , 1986, Journal of cellular biochemistry.
[7] M. Duffy,et al. Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report , 1988, Cancer.
[8] J. Foekens,et al. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. , 1989, Cancer research.
[9] S. Stacey,et al. Plasminogen activator inhibitors: hormonally regulated serpins , 1990, Molecular and Cellular Endocrinology.
[10] K. Ulm,et al. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer , 1990 .
[11] F. Jänicke,et al. Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer , 1991, Seminars in thrombosis and hemostasis.
[12] J. Foekens,et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. , 1992, Cancer research.
[13] F. Jänicke,et al. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. , 1993, The Journal of clinical investigation.
[14] D. Rifkin,et al. Biology and biochemistry of proteinases in tumor invasion. , 1993, Physiological reviews.
[15] J. Foekens,et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] F. Spyratos,et al. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. , 1994, British Journal of Cancer.
[17] S. Rosenberg,et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. , 1994, The Journal of biological chemistry.
[18] P. Quax,et al. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. , 1994, Gastroenterology.
[19] F. Blasi,et al. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation. , 1995, Biological chemistry Hoppe-Seyler.
[20] G. Liu,et al. Co‐expression of urokinase, urokinase receptor and PAI‐1 is necessary for optimum invasiveness of cultured lung cancer cells , 1995, International journal of cancer.
[21] N. Brünner,et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] J. Foekens,et al. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. , 1995, Journal of the National Cancer Institute.
[23] F. Blasi,et al. The urokinase/urokinase-receptor system and cancer invasion. , 1995, Bailliere's clinical haematology.
[24] M. Duffy,et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer , 1995, International journal of cancer.
[25] J. Foekens,et al. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. , 1995, Cancer research.
[26] M. Ploug,et al. The Urokinase Receptor. Protein Structure and Role in Plasminogen Activation and Cancer Invasion , 1995 .
[27] Michael V. Doyle,et al. Regulation of Integrin Function by the Urokinase Receptor , 1996, Science.
[28] D. Lawrence,et al. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. , 1996, Nature.
[29] K. Preissner,et al. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. , 1996, Experimental cell research.
[30] M. Duffy,et al. Proteases as prognostic markers in cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] D. Loskutoff,et al. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? , 1996, The Journal of cell biology.
[32] T. Powles. Adjuvant therapy for early breast cancer: a time to refine. , 1997, Journal of the National Cancer Institute.
[33] H. Höfler,et al. Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.
[34] D. Wallwiener,et al. Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. , 1997, British Journal of Cancer.
[35] M. Duffy,et al. The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.
[36] H. Chapman,et al. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. , 1997, Current opinion in cell biology.
[37] H. Nielsen,et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. , 1997, Clinical chemistry.
[38] K. Preissner,et al. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. , 1997, Experimental cell research.
[39] N. Brünner,et al. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. , 1997, European journal of cancer.
[40] N. Brünner,et al. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] M. Skobe,et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization , 1998, Nature Medicine.
[42] N. Brünner,et al. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. , 1998, British Journal of Cancer.
[43] H. Nielsen,et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. , 1999, Journal of the National Cancer Institute.
[44] V. Bécette,et al. Dissemination risk index based on plasminogen activator system components in primary breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Stefano Forti,et al. Novel methods for the determination of the angiogenic activity of human tumors , 2004, Breast Cancer Research and Treatment.
[46] D.,et al. Regression Models and Life-Tables , 2022 .